23AndMe lays off 100 as demand for DNA testing declines

23AndMe lays off 100 as DNA testing demand declines

Citing declining sales, home DNA-testing company 23andMe announced plans Thursday to layoff 100 employees, or roughly 14 percent of its staff.

According to CNBC, the company plans in the coming months to tighten its focus on the direct-to-consumer business as well as its therapeutics division, while scaling back its clinical studies segment. At least some of the layoffs will affect the 23andMe’s operations team.

“This has been slow and painful for us,” 23andMe CEO Anne Wojcicki told CNBC.

Content Continues Below

According to CNN, the company has raised hundreds of millions of dollars in venture capital and rates as one of technology’s “unicorn” companies, or startups valued at $1 billion or more.

Wojcicki told both outlets she considered the market swing “shocking” and said everything from privacy concerns to public fear of an economic downturn could be driving the downward shift.

Read more here and here.

Low-angle view of logo on facade of personal genomics company 23AndMe in the Silicon Valley town of Mountain View, California, October 28, 2018. (Photo by Smith Collection/Gado/Getty Images)
Low-angle view of logo on facade of personal genomics company 23AndMe in the Silicon Valley town of Mountain View, California, October 28, 2018. (Photo by Smith Collection/Gado/Getty Images) (Smith Collection/Gado/Getty Images)